Trials in people
To develop new medicines and vaccines, GSK works closely with healthcare professionals to carry out investigational testing of new treatments in clinical trials.
Clinical trials involving human beings are governed by strict local and international regulations. Throughout each trial the proceedings are monitored by government authorities as well as GSK’s own Global Safety Board.
There are always at least three phases to clinical trials. Occasionally, a fourth phase might be necessary if we think the medicine can be improved, or if we need to provide answers to questions from the regulatory authorities.
Visit the global site for more information on clinical trial phases, who takes part in them and how they are monitored. You can also learn more about how we work with healthcare professionals on these projects.
If you are interested in becoming a research volunteer, see which current trials operating in New Zealand.
GSK Global Clinical Study Register
As part of our commitment to transparency in business, we publicly disclose all of our clinical research and trials, whether the results reflect positively or negatively on our medicines.
We believe sharing this research is essential to making advancements in medical science, and it is also the best way to let prescribers and patients know about scientific findings on our medicines as part of our transparent approach to what we do.
Our Clinical Study Register website is a resource for researchers, medical professionals and the public to access this data from GSK-sponsored clinical studies.
The Register includes:
- protocol summaries for ongoing studies (a brief description of what is being researched and what the study is designed to discover)
- results from completed clinical studies on compounds that are both investigational and approved medicines
- results of observational research (studies of GSK medicines) and meta-analyses (which combine and analyse the results from two or more previous studies)
- results from studies of terminated medicines - this informs the scientific community about non-productive areas of research and may reduce exposure of volunteers to similar compounds
- the names of principal investigators who participate in our clinical research
View the Clinical Study Register